{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+hematopoietic+stem+cell+transplant&page=25",
    "query": {
      "intervention": "Allogeneic hematopoietic stem cell transplant",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 1172,
    "total_pages": 118,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+hematopoietic+stem+cell+transplant&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+hematopoietic+stem+cell+transplant&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T16:04:17.988Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00686556",
      "title": "Total Marrow Irradiation for Refractory Acute Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Myelodysplastic Syndrome",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "total marrow irradiation",
          "type": "RADIATION"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Granulocyte colony-stimulating factor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HLA-matched related donor bone marrow",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2012-08",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-10-14T16:04:17.988Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00686556"
    },
    {
      "nct_id": "NCT00008450",
      "title": "Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenosine Deaminase Deficiency",
        "Autosomal Recessive Disorder",
        "Immune System Disorder",
        "Purine-Nucleoside Phosphorylase Deficiency",
        "Severe Combined Immunodeficiency",
        "Severe Combined Immunodeficiency With Absence of T and B Cells",
        "X-Linked Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Allogeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 6,
      "start_date": "1997-08-11",
      "completion_date": "2018-12-26",
      "has_results": false,
      "last_update_posted_date": "2019-07-29",
      "last_synced_at": "2026-10-14T16:04:17.988Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00008450"
    },
    {
      "nct_id": "NCT03263442",
      "title": "High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic Stem Cell Transplantation",
        "Delirium",
        "Thiamine Deficiency"
      ],
      "interventions": [
        {
          "name": "Thiamine",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2017-10-16",
      "completion_date": "2020-08-10",
      "has_results": true,
      "last_update_posted_date": "2021-10-19",
      "last_synced_at": "2026-10-14T16:04:17.988Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03263442"
    },
    {
      "nct_id": "NCT01001780",
      "title": "Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Active Chronic Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Pentostatin; Cyclophosphamide; Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-08",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2013-10-16",
      "last_synced_at": "2026-10-14T16:04:17.988Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01001780"
    },
    {
      "nct_id": "NCT05509582",
      "title": "Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Mediated Anemia",
        "Immune Mediated Thrombocytopenia",
        "Chronic GVHD"
      ],
      "interventions": [
        {
          "name": "fostamatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2025-11-07",
      "completion_date": "2025-11-07",
      "has_results": false,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-14T16:04:17.988Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05509582"
    },
    {
      "nct_id": "NCT06149403",
      "title": "A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "MPS-IH (Hurler Syndrome)"
      ],
      "interventions": [
        {
          "name": "Experimental: OTL-203",
          "type": "GENETIC"
        },
        {
          "name": "Active Comparator: Allo-HSCT",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Orchard Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "28 Days",
        "maximum_age": "30 Months",
        "sex": "ALL",
        "summary": "28 Days to 30 Months"
      },
      "enrollment_count": 41,
      "start_date": "2023-12-11",
      "completion_date": "2031-03",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-10-14T16:04:17.988Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06149403"
    },
    {
      "nct_id": "NCT03488862",
      "title": "Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 34,
      "start_date": "2018-03-01",
      "completion_date": "2020-10-28",
      "has_results": false,
      "last_update_posted_date": "2021-01-13",
      "last_synced_at": "2026-10-14T16:04:17.988Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03488862"
    },
    {
      "nct_id": "NCT01860170",
      "title": "Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematological Malignancy"
      ],
      "interventions": [
        {
          "name": "Cohort 1-Bortezomib (Velcade ®)",
          "type": "DRUG"
        },
        {
          "name": "Cohort 2-Bortezomib (Velcade ®)",
          "type": "DRUG"
        },
        {
          "name": "Cohort 3-Bortezomib (Velcade ®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corewell Health West",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2012-04",
      "completion_date": "2018-03",
      "has_results": true,
      "last_update_posted_date": "2023-06-02",
      "last_synced_at": "2026-10-14T16:04:17.988Z",
      "location_count": 1,
      "location_summary": "Grand Rapids, Michigan",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01860170"
    },
    {
      "nct_id": "NCT00028730",
      "title": "Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 25,
      "start_date": "2001-08",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2015-12-22",
      "last_synced_at": "2026-10-14T16:04:17.988Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00028730"
    },
    {
      "nct_id": "NCT00201799",
      "title": "Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft-Versus-Host Disease"
      ],
      "interventions": [
        {
          "name": "Infliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2004-02",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2015-06-10",
      "last_synced_at": "2026-10-14T16:04:17.988Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00201799"
    }
  ]
}